We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
226
Biohaven
BHVN
$2.21B
$10.9K ﹤0.01%
+200
New +$9.9K
GLSTR
227
DELISTED
Global Star Acquisition, Inc. Right
GLSTR
$10.7K ﹤0.01%
118,400
– –
AUPH icon
228
Aurinia Pharmaceuticals
AUPH
$2.11B
$10K ﹤0.01%
+2,000
New +$13.6K
ACAD icon
229
Acadia Pharmaceuticals
ACAD
$5.03B
$9.24K ﹤0.01%
+500
New +$12.4K
TMTCR
230
DELISTED
TMT Acquisition Corp Rights
TMTCR
$8.98K ﹤0.01%
49,900
– –
MRVI icon
231
Maravai LifeSciences
MRVI
$919M
$8.67K ﹤0.01%
+1,000
New +$6.77K
DYN icon
232
Dyne Therapeutics
DYN
$4.9B
$8.43K ﹤0.01%
+297
New +$6.72K
TARA icon
233
Protara Therapeutics
TARA
$232M
$8.02K ﹤0.01%
2,000
-194
-9% -$626
SRZN icon
234
Surrozen
SRZN
$301M
$7.07K ﹤0.01%
+450
New +$5.04K
BOLT icon
235
Bolt Biotherapeutics
BOLT
$7.78M
$7K ﹤0.01%
+250
New +$5.79K
BLUE
236
DELISTED
bluebird bio
BLUE
$6.4K ﹤0.01%
+250
New +$6.41K
OAKUR
237
DELISTED
Oak Woods Acquisition Corp Right
OAKUR
$6K ﹤0.01%
30,000
– –
MASI
238
DELISTED
Masimo
MASI
$5.58K ﹤0.01%
38
-20
-34% -$2.58K
TSVT
239
DELISTED
2seventy bio
TSVT
$5.35K ﹤0.01%
1,000
– –
ADXN
240
Addex Therapeutics
ADXN
$4.99K ﹤0.01%
+390
New +$3.84K
BYND icon
241
Beyond Meat
BYND
$277M
$4.78K ﹤0.01%
+577
New +$4.44K
GERN icon
242
Geron
GERN
$949M
$4.27K ﹤0.01%
1,295
-16,000
-93% -$35.8K
ICHR icon
243
Ichor Holdings
ICHR
$2.56B
$4.17K ﹤0.01%
+108
New +$4.18K
CALC icon
244
CalciMedica
CALC
$10.9M
$3.25K ﹤0.01%
+781
New +$3.57K
RLMD icon
245
Relmada Therapeutics
RLMD
$527M
$2.79K ﹤0.01%
601
-58,000
-99% -$279K
TLIS
246
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$2.63K ﹤0.01%
+300
New +$2.47K
EMCGR
247
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$2.52K ﹤0.01%
18,000
– –
KPTI icon
248
Karyopharm Therapeutics
KPTI
$48M
$2.23K ﹤0.01%
+99
New +$1.74K
GLSTW
249
DELISTED
Global Star Acquisition, Inc. Warrants
GLSTW
$1.96K ﹤0.01%
120,000
– –
FLFVR
250
DELISTED
Feutune Light Acquisition Corporation Right
FLFVR
$1.28K ﹤0.01%
15,000
– –
8 9
10
11 12

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.